Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

NCT01275287 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped the study failed to enroll any patient and sponsor wished to stop.

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

DRUG: Standard of care treatment
DRUG: eculizumab

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]
[object Object]
[object Object]